Biomaterial Database

[Diabetic dyslipoproteinemia]. 2011

Klaus G Parhofer

Medizinische Klinik II-Grosshadern, Klinikum der Universität München. klaus.parhofer@med.uni-muenchen.de

UI	MeSH Term	Description	Entries
D012016	Reference Values	The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality.	Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D002784	Cholesterol	The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils.	Epicholesterol
D003324	Coronary Artery Disease	Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.	Arteriosclerosis, Coronary,Atherosclerosis, Coronary,Coronary Arteriosclerosis,Coronary Atherosclerosis,Left Main Coronary Artery Disease,Left Main Coronary Disease,Left Main Disease,Arterioscleroses, Coronary,Artery Disease, Coronary,Artery Diseases, Coronary,Atheroscleroses, Coronary,Coronary Arterioscleroses,Coronary Artery Diseases,Coronary Atheroscleroses,Left Main Diseases
D003925	Diabetic Angiopathies	VASCULAR DISEASES that are associated with DIABETES MELLITUS.	Diabetic Vascular Complications,Diabetic Vascular Diseases,Microangiopathy, Diabetic,Angiopathies, Diabetic,Angiopathy, Diabetic,Diabetic Angiopathy,Diabetic Microangiopathies,Diabetic Microangiopathy,Diabetic Vascular Complication,Diabetic Vascular Disease,Microangiopathies, Diabetic,Vascular Complication, Diabetic,Vascular Complications, Diabetic,Vascular Disease, Diabetic,Vascular Diseases, Diabetic
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000960	Hypolipidemic Agents	Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS.	Antihyperlipidemic,Antilipemic,Antilipemic Agents,Antilipemic Drug,Hypolipidemic Agent,Hypolipidemic Drug,Antihyperlipemics,Antihyperlipidemics,Antilipemic Drugs,Antilipemics,Hypolipidemic Drugs,Agent, Hypolipidemic,Agents, Antilipemic,Agents, Hypolipidemic,Drug, Antilipemic,Drug, Hypolipidemic,Drugs, Antilipemic,Drugs, Hypolipidemic
D014280	Triglycerides	An ester formed from GLYCEROL and three fatty acid groups.	Triacylglycerol,Triacylglycerols,Triglyceride
D050171	Dyslipidemias	Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.	Dyslipoproteinemias,Dyslipidemia,Dyslipoproteinemia

Related Publications

Klaus G Parhofer

[Diabetic dyslipoproteinemia: beyond LDL].

May 2009, Deutsche medizinische Wochenschrift (1946),

Klaus G Parhofer

Treatment of diabetic dyslipoproteinemia.

August 2003, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association,

Klaus G Parhofer

[Dyslipoproteinemia and diabetic nephropathy].

January 1991, Diabete & metabolisme,

Klaus G Parhofer

Dyslipoproteinemia in diabetic renal failure.

December 1992, Kidney international,

Klaus G Parhofer

[Diabetic dyslipoproteinemia: physiopathological bases and treatment prospects].

January 2001, Fortschritte der Medizin. Originalien,

Klaus G Parhofer

[Relationship between platelet hyperactivation and dyslipoproteinemia in diabetic nephropathy].

April 1992, Orvosi hetilap,